hotspot -WSS

hotspot

author：comprehensive 2025-09-29 21:25:26 - browse：9

the Federal Trade Commission building and its brown sign — Adobe

A federal judge ordered Wednesday that Novant Health can move forward with its plan to buy two North Carolina hospitals, denying the Federal Trade Commission’s request for an injunction.

The FTC sued to block the deal in January, arguing that it would give Novant control of more than 65% of the region’s inpatient market. The case, one seeking to block nearby hospitals from merging and creating an even more powerful dominant player, is the FTC’s bread and butter. The agency has shied away from challenging cross-market and vertical mergers, but this one is right in its wheelhouse, which makes the setback surprising.

Under the deal, announced early last year, Novant would buy two hospitals in the same county from for-profit Community Health Systems for $320 million. The hospitals, Lake Norman Regional Medical Center and Davis Regional Medical Center, are only a 25-minute drive from one another. Davis Regional used to be a full-service hospital, but is now a psychiatric hospital. The deal also includes a group of 24 doctors, a majority interest in an endoscopy center, and a holding in a planned surgery center.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Second xenotransplant done with gene

knowledge

WSS

Hey, doctors: Don't be no

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Trump Organization, Michael Cohen agree to settle million

Readout LOUD podcast: possible new ALS drug, artificial wombs

Biden White House, tech companies launch new safeguards around emerging AI technology

It's time to take a new tack for treating Alzheimer's

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

At least 13 dead in Texas as scorching temps continue

Microbiome research is starting to find links to chronic diseases

Wildfire smoke exposes gaps in outdoor worker protections

FDA panel to weigh approval of NurOwn, controversial ALS drug

State Dept. review finds Biden bears some blame for Afghanistan failures

Senate HELP committee spars over health care workforce policies

Medical leaders decry Supreme Court decision on affirmative action

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

Jerome Adams on the need for new antivirals for Covid

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Wikipedia

Second xenotransplant done with gene

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Senators: Long

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Biotech stock slump in 2023: awaiting the turnaround

'The View' co

explore

knowledge

focus

focus